Advertisement Fidelity
Home > Boards > US Listed > Biotechs >

Advaxis, Inc. (ADXS)

Add ADXS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator jaxstraw, roberteliates, MissionIR
Search This Board:
Last Post: 4/15/2014 10:38:36 PM - Followers: 130 - Board type: Free - Posts Today: 0

Advaxis is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company's immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research - UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis' lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today's most challenging diseases.

Additional Resources

Company Website
Latest Press Releases
Events & Presentation
Fact Sheet

Advaxis Milestones

Report Phase 2 mid-dose CIN 2/3 data Q1 2013
Submit PSA IND Q1 2013
Initiate Phase 1 for PSA Q2 2013
Update Phase 2 cervical cancer data Q2 2013
Complete Phase 2 Cervical Cancer Study Q2 2013
Report Phase 2 high-dose CIN 2/3 data Q2 2013

Advaxis Partners

National Cancer Institute
Gynecologic Oncology Group

Advaxis is collaborating with the GOG to conduct a multi-center, Phase 2 clinical trial of ADXS-HPV, our Lm-LLO based immunotherapy targeted to HPV, in patients with recurrent or refractory cervical cancer who have failed prior cytotoxic therapy. This Phase 2 trial is underwritten by GOG and will be conducted by GOG investigators. This patient population is similar to the patient population in the cervical cancer study being conducted in India as well as the patients in the Phase 1 trial of ADXS-HPV.

Cancer Research UK
Cancer Research UK (CRUK), the UK organization dedicated to cancer research, is conducting a clinical trial to investigate the use of ADXS-HPV, our Lm-LLO based immunotherapy targeted to HPV, for the treatment of head and neck cancer. This Phase 1/2 clinical trial will investigate the safety and efficacy of ADXS-HPV in head and neck cancer patients who have previously failed treatment with surgery, radiotherapy and chemotherapy - alone or in combination. The study is to be conducted at 3 sites in the UK (Aintree Hospital at the University of Liverpool, The Royal Marsden Hospital in London, and Cardiff Hospital at the University of Wales).

Montefiore Medical Center
Advaxis is collaborating with Dr. Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop the ADXS-PSA construct for the treatment of prostate cancer.

Montefiore Medical Center
Advaxis is collaborating with Dr. Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop the ADXS-PSA construct for the treatment of prostate cancer.

Karolinska Institutet
Advaxis is collaborating with the laboratory of Professor Marianne van Hage at the Karolinska Intitutet in Stockholm, Sweden to evaluate the potential of Advaxis immunotherapies to treat and prevent allergies in established scientific models of allergic diseases. Prof. Marianne van Hage's research is focused on further understanding the molecular mechanisms of underlying allergic disease and the function of allergens, and to develop new diagnostic markers and new strategies for vaccination.

University of Pennsylvania School
of Veterinary Medicine

Advaxis is collaborating with Dr. Nicola Mason at the University of Pennsylvania School of Veterinary Medicine to study the ADXS-HER2 construct for the treatment of canine osteosarcoma in large breed companion dogs.

National Cancer Institute Vaccine Section
Advaxis has a Collaborative Research and Development Agreement (CRADA) with the Vaccine Section of the National Cancer Institute for the development of Advaxis immunotherapies. NCI will use different in vitro and in vivo models to elucidate the effect of our immunotherapies on many different types of immune cells. They will also investigate the mechanisms by which they might reduce immune inhibition that protects tumors from immune attack. The work is intended to enhance the anti-tumor effects of Advaxis immunotherapies and alter the tumor microenvironment, enabling them to be used with other methods of cancer treatment.

Wistar Institute
Advaxis is collaborating with the Wistar Institute to explore the potential of FAP as a target for immune attack and as the basis for the development of an Advaxis immunotherapy. Therapeutically targeting FAP (fibroblast activation protein) might significantly reduce tumor growth, as it has in some mouse studies.

Wistar Institute
Advaxis is collaborating with the Wistar Institute to explore the potential of FAP as a target for immune attack and as the basis for the development of an Advaxis immunotherapy. Therapeutically targeting FAP (fibroblast activation protein) might significantly reduce tumor growth, as it has in some mouse studies.

University of British Columbia
Advaxis is collaborating with the laboratory of Dr. Tobias Kollmann at the University of British Columbia to develop Advaxis immunotherapies for the treatment of infectious disease and to develop new dosage forms. Dr. Kollmann is an immunologist and neonatal vaccinologist who has published extensively on the use of Listeria immunotherapies as potential therapeutic agents for the treatment of childhood diseases. Dr. Kollmann will use our proprietary immunotherapy vectors for the development of novel infectious disease applications.

Management Team

Thomas A. Moore, Chairman / CEO

On December 15, 2006, Thomas Moore was named our Chairman and Chief Executive Officer. He also serves as Chairman of the Board of Directors of Mayan Pigments, Inc., which has developed and patented Mayan pigment technology. Previously, from June 2002 to June 2004 Mr. Moore was President and Chief Executive Officer of Biopure Corporation, a developer of oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. From 1996 to November 2000 he was President and Chief Executive Officer of Nelson Communications. Previously, Mr. Moore had a 23-year career with the Procter & Gamble Company in multiple managerial positions, including President of Health Care Products where he was responsible for prescription and over-the-counter medications worldwide, and group vice president of the Procter & Gamble Company.

Mark J. Rosenblum, CFO, Secretary, Senior VP

Mr. Rosenblum joined Advaxis in January 2010 as Chief Financial Officer, Senior Vice President, and Secretay. Prior to Advaxis, Mr. Rosenblum managed financial operations on behalf of an early stage publicly traded biotech headquartered in Dallas, Texas. From August 1985 through June 2003, he served in various financial leadership positions at Wellman, Inc., a chemical and recycling company. As a corporate controller for Wellman, he participated in the company's transition from a $125 million privately held plastic recycling company into a publicly traded corporation with an excess of $400 million in revenue. In 1989, Wellman acquired the polyester assets of a former Celanese Corporation spin-off for over $550 million. Mr. Rosenbum became Vice President, Corporate Controller. Following that acquisition, the company reached almost $1 billion in revenue. In 1996, he was promoted to the position of Chief Accounting Officer, serving in that role until 2003. Mr. Rosenblum's career has afforded him the opportunity to serve as a hands-on financial leader, participating in Wellman's active M&A strategy, and managing the divestures for Wellman while the company navigated both the declining US textile business and the growing PET plastics packaging business. Before joining Wellman, Mark was a plant financial controller for Celanese Corp. Prior to his chemical industry experience, Mr. Rosenblum was in the public accounting profession, beginning his career with Haskins and Sells (now Deloitte and Touche) in their New York office in 1977. Mr. Rosenblum holds both a BS and Masters of Accountancy from the University of South Carolina and has been a CPA for over 30 years.

John Rothman, Ph.D., Executive VP of Science & Operations

Dr. John Rothman is currently EVP of Science & Operations at Advaxis Inc,. He was Director of Clinical Drug Development, and then Sr. Director of all of Roche's data collection, analysis, and report writing. He was a senior scientist at Hoffmann-LaRoche working with recombinant agents provided by Genentech, where his work with interferon-a (Roferon-A) in AIDS related Kaposi's sarcoma became the basis for the first BLA. Dr. Rothman was a member of the first clinical group to develop genetically recombinant pharmaceutical agents and test them in human disease at Schering Plough using Biogen's a-interferon, where was the monitor for the first clinical trial in AIDS in 1984. He studied at the Department of Pharmacology at the Tulane University School of Medicine in the laboratory of Dr. Louis Ignarro (Nobel Prize; Medicine, 1998) and conducted his dissertation research at the New Orleans V.A. Hospital laboratory of Dr. Andrew Schally (Nobel Prize; Medicine, 1977). He has developed many different pharmaceutical agents in many disciplines including infectious disease, gastroenterology, neurology, oncology and virology.

Robert Petit, Ph.D., VP Clinical Operations & Medical Affairs

Dr. Robert Petit has 23 years of experience in all medical and scientific aspects of pharmaceutical development. He has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from phase I to IV. Dr. Petit joins Advaxis from Bristol Myers Squibb where he was the U.S. Medical Strategy Lead for the Ipilimumab program, director of Medical Strategy for New Oncology Products, and director of Global Clinical Research. Prior to joining Bristol Myers-Squibb, Robert served as vice president of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Robert has had significant FDA experience and has contributed to five NDA/BLA filings. Dr. Petit has a Doctorate from the Ohio State University College of Medicine and a B.S. from Indiana State University.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#2726  Sticky Note Advaxis’ ADXS-HPV Granted Orphan Drug Designation for Treatment Big Barnie 08/14/13 09:01:10 AM
#3057   I follow quite a few small cap biotech's g_stell 04/15/14 10:38:36 PM
#3056   LOL I know how you feel; I say John_Langston 04/15/14 08:02:23 PM
#3055   Bad news. I have been following this stock g_stell 04/15/14 06:33:47 PM
#3054   Thanks for posting this article. ADXS and inveterate 04/15/14 08:41:59 AM
#3053   Wtf is happening to the stock price? larrito 04/14/14 03:45:48 PM
#3052 stills999 04/14/14 01:20:11 PM
#3051   Both award winning vaccins target a different type alexander77 04/14/14 12:59:34 PM
#3050 stills999 04/14/14 12:55:45 PM
#3049   Hi, Alexander & Inveterate. terry hallinan 04/13/14 01:31:53 PM
#3048   Advaxis vaccine has been awarded as best therapeutic alexander77 04/13/14 12:26:17 PM
#3047   Can anyone with more medical knowledge than I, inveterate 04/13/14 11:10:33 AM
#3046   They don't have to restore analyst confidence though, alexander77 04/11/14 10:41:01 PM
#3045   I hope you are right. It will inveterate 04/11/14 07:41:04 PM
#3044   Very smart move of the CEO!The CEO did alexander77 04/11/14 06:14:25 AM
#3043   Could be; I bought my shares for what John_Langston 03/28/14 08:00:10 PM
#3042   Aegis did issue buy rating with Target James salmon 03/28/14 07:50:04 PM
#3041   Wonder why Aegis exercised their full option to John_Langston 03/28/14 06:27:12 PM
#3040   Looks like a great buying opportunity here. John_Langston 03/28/14 06:21:16 PM
#3039   Looks great John_Langston 03/28/14 10:05:36 AM
#3038   Here is a list of all institutional holders alexander77 03/28/14 09:24:27 AM
#3037   A strong cash position for a company with alexander77 03/28/14 05:06:08 AM
#3036   Aegis price target is + 10 dollar/share. alexander77 03/27/14 11:36:13 PM
#3035   Prepare to lose $ John_Langston 03/27/14 07:16:06 PM
#3034   Prepare to lose $ DR Ryan 03/27/14 07:12:29 PM
#3033   I personally would be prepared for a little HHHG 03/27/14 04:46:44 PM
#3032   I hope so; I bought 7k shares today John_Langston 03/27/14 04:46:17 PM
#3031   People,today we have seen the bottom. alexander77 03/27/14 04:13:48 PM
#3030   Thanks a whole heap, Inveterate. terry hallinan 03/27/14 11:04:18 AM
#3029   That is the only possible explanation that makes inveterate 03/27/14 08:59:22 AM
#3028   Aegis and Noble must have known this was James salmon 03/27/14 08:53:14 AM
#3027   Last filing showed they had 15 million and James salmon 03/27/14 08:50:47 AM
#3026   That is the only thing that would make inveterate 03/27/14 08:48:45 AM
#3025   I wish I could offer some advice to James salmon 03/27/14 08:44:54 AM
#3024   Any advice out there? This has become inveterate 03/27/14 08:12:45 AM
#3023   I wish the market had shown a more inveterate 03/20/14 08:42:24 PM
#3022   Agreed, this is a significant development that will fbg0316 03/19/14 10:07:33 PM
#3021   Big news tonight re vet deal. Must admit James salmon 03/19/14 09:07:09 PM
#3020   The proposed OIP increase is not just excessive, fbg0316 03/11/14 09:09:21 PM
#3019   James: When do you anticipate we will see a Big Barnie 03/11/14 02:10:13 PM
#3018   Do you see any other catalysts that might inveterate 03/11/14 01:54:20 PM
#3017   I think over the last few sessions a James salmon 03/11/14 11:46:12 AM
#3016   what is a decent entry point> Just some nymostwanted 03/08/14 05:26:03 PM
#3015   Advaxis Cancer Vaccine Has Gone To The Dogs terry hallinan 03/03/14 10:43:19 AM
#3014 inveterate 03/02/14 05:45:47 PM
#3013   the threatened shareholder lawsuit jaxstraw 03/02/14 03:52:57 PM
#3012   Do you think this could have something to inveterate 03/01/14 01:52:19 PM
#3011   Could you explain what you mean by "confidential inveterate 03/01/14 01:04:17 PM
#3010   Hi, Tom. terry hallinan 02/28/14 02:46:21 PM
#3009   Take a look at the DEF 14A also tomlewis727 02/28/14 01:28:32 PM
#3008   Confidential treatment order this morning, wonder what that's James salmon 02/28/14 12:34:45 PM